80
Participants
Start Date
October 3, 2023
Primary Completion Date
February 22, 2032
Study Completion Date
February 22, 2032
Elranatamab
Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
NOT_YET_RECRUITING
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
RECRUITING
St. David's South Austin Medical Center, Austin
RECRUITING
Longs Peak Hospital, Longmont
RECRUITING
UCHealth Longs Peak Medical Center, Longmont
RECRUITING
UCHealth Poudre Valley Hospital, Fort Collins
RECRUITING
UCHealth Harmony, Fort Collins
RECRUITING
UCHealth - Medical Center of the Rockies, Loveland
RECRUITING
UCHealth Greeley Hospital, Greeley
RECRUITING
Peking University Third Hospital, Beijing
RECRUITING
Shandong Provincial Hospital, Jinan
RECRUITING
The first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Arthur J.E. Child Comprehensive Cancer Centre, Calgary
RECRUITING
Cross Cancer Institute, Edmonton
RECRUITING
McGill University Health Centre, Montreal
RECRUITING
Japanese Red Cross Medical Center, Shibuya-ku
RECRUITING
University Hospital,Kyoto Prefectural University of Medicine, Kyoto
Lead Sponsor
Pfizer
INDUSTRY